<DOC>
	<DOCNO>NCT02373098</DOCNO>
	<brief_summary>The main purpose study measure serum level cytokine chemokines know increase multiple sclerosis relapse . Cytokines broad loose category small proteins important cell signal . The second purpose study test cytokine/chemokine change measure 3rd 6th month efficacy parameter .</brief_summary>
	<brief_title>Fingolimod Effect Cytokine Chemokine Levels</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>1 . Written informed consent must obtain begin te study 2 . Nonresponder RRMS patient 3 . Last relapse patient least 2 month study entry . 4 . Last interferon glatiramer acetate dose patient least 1 month study entry . Other protocoldefined inclusion criterion may apply 1 . Patients secondary progressive MS. 2 . Patients known contraindication fingolimod treatment . 3 . Other coexistent autoimmune diseases 4 . Pregnant nursing ( lactate ) woman Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fingolimod , cytokine , chemokine , RRMS</keyword>
</DOC>